Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Total Current Liabilities: 2010-2024

Historic Total Current Liabilities for Anika Therapeutics (ANIK) over the last 15 years, with Dec 2024 value amounting to $23.3 million.

  • Anika Therapeutics' Total Current Liabilities fell 25.12% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.1 million, marking a year-over-year decrease of 25.12%. This contributed to the annual value of $23.3 million for FY2024, which is 24.96% down from last year.
  • Per Anika Therapeutics' latest filing, its Total Current Liabilities stood at $23.3 million for FY2024, which was down 24.96% from $31.1 million recorded in FY2023.
  • Anika Therapeutics' Total Current Liabilities' 5-year high stood at $36.9 million during FY2020, with a 5-year trough of $23.3 million in FY2024.
  • Over the past 3 years, Anika Therapeutics' median Total Current Liabilities value was $27.9 million (recorded in 2022), while the average stood at $27.4 million.
  • Per our database at Business Quant, Anika Therapeutics' Total Current Liabilities soared by 126.50% in 2020 and then fell by 24.96% in 2024.
  • Yearly analysis of 5 years shows Anika Therapeutics' Total Current Liabilities stood at $36.9 million in 2020, then declined by 19.18% to $29.8 million in 2021, then declined by 6.31% to $27.9 million in 2022, then grew by 11.27% to $31.1 million in 2023, then fell by 24.96% to $23.3 million in 2024.